Roquefort Therapeutics (LON:ROQ) Stock Price Up 3.9% – Here’s Why

Roquefort Therapeutics plc (LON:ROQ) shares traded up 3.9% during trading on Monday . The stock traded as high as GBX 1.50 and last traded at GBX 1.46. 1,882,007 shares traded hands during trading, an increase of 14% from the average session volume of 1,649,303 shares. The stock had previously closed at GBX 1.40.

Roquefort Therapeutics Stock Up 3.9%

The firm has a market capitalization of £2.29 million, a PE ratio of -2.31 and a beta of 0.05. The company has a fifty day simple moving average of GBX 1.58 and a two-hundred day simple moving average of GBX 1.66. The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79.

Insiders Place Their Bets

In other Roquefort Therapeutics news, insider Dr Darrin Disley bought 5,000,000 shares of the company’s stock in a transaction on Friday, November 21st. The shares were bought at an average cost of GBX 170 per share, for a total transaction of £8,500,000. 23.53% of the stock is currently owned by company insiders.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.